| Similar Articles |
|---|
 |
The Motley Fool
March 23, 2007
Brian Lawler |
Ligand's Big Payout Ligand decides to return some cash to shareholders.   |
The Motley Fool
March 26, 2007
Rich Duprey |
Acquisitions Mark Pharmaceutical Industry Japan's Eisai's newest acquisition continues the trend of pharmaceuticals buying up biotechs. Investors, take note. |
The Motley Fool
November 13, 2006
Brian Lawler |
King Not Loving Its Shareholders King Pharmaceuticals appears to be a company with stagnating operations, trying to grow sales via licensing or acquiring new drugs, with (at best) a shaky handling of its accounting practices. Investors, take note. |
The Motley Fool
July 2, 2010
Brian Orelli |
Arena Got Taken A billion-dollar market and that's all the pharmaceuticals company could get? |
The Motley Fool
August 25, 2008
Brian Lawler |
King Triples Down King Pharmaceuticals makes a risky all-in bet on an unproven market. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
The Motley Fool
March 3, 2009
Robert Steyer |
Seeking Gain From Pain King Pharmaceuticals tries to remake itself as a pain therapy company. |
The Motley Fool
January 21, 2005
Rich Duprey |
Cardinal Back in the Nest Drug distributor and Japanese pharma Eisai come to agreement after all. |
The Motley Fool
November 2, 2006
Rich Duprey |
Eisai Profits From Demand The Japanese pharmaceutical reports strong profits on increased demand for Alzheimer's treatment. Investors, take note. |
The Motley Fool
May 15, 2007
Rich Duprey |
Eisai Doles Out Tough Medicine The Japanese pharmaceutical company wins a patent infringement decision regarding its heartburn treatment. Investors, take note. |
The Motley Fool
June 23, 2008
Brian Lawler |
Wait a Little Longer, Ligand The FDA delays its review of GlaxoSmithKline and partner Ligand Pharmaceutical's blood-disorder drug Promacta. |
The Motley Fool
August 6, 2004
Zeke Ashton |
Are Biotechs Worth the Risk? Even when their drugs are doing well, companies in this industry don't necessarily yield big rewards for investors. |
The Motley Fool
February 25, 2010
Brian Orelli |
An Untouched Market Waiting to Be Captured Unfilled prescriptions are a potential boon to drug companies. |
The Motley Fool
March 25, 2009
Brian Orelli |
The FDA Leaves Pfizer in the Waiting Room The EU loves its new osteoporosis drug, but what about the U.S.? |
The Motley Fool
December 12, 2005
Rich Duprey |
Patent? What Patent? Japanese drug firm Eisai sues Teva over a patented Alzheimer's treatment. Investors, take note. |
The Motley Fool
January 8, 2008
Brian Orelli |
Brits May Bludgeon Drug Companies The U.K.'s National Health Service delivers a shock to drugmakers; it is considering a 10% drop in the rate that it pays for drugs, to help it reach its goal of a 3% reduction in the nation's overall health-care bill. |
The Motley Fool
August 3, 2004
Charly Travers |
Black Cloud Over Ligand The pharmaceuticals company misses estimates and loses an auditor. Many investors are going to be skeptical about whether guidance will be met. |
The Motley Fool
February 27, 2009
Brian Orelli |
Can $634 Billion Save the U.S. Health Care System? The good news is that Obama's budget includes a $634 billion down payment on getting insurance for the 48 million uninsured. The bad news is that the president has to pay for that by cutting costs in other areas. |
The Motley Fool
August 19, 2011
Cindy Johnson |
12 Biotech Stocks the Insiders Are Buying Folks in the know think these biotech stocks will rise. Should you join them? |
The Motley Fool
August 13, 2007
Rich Duprey |
U.K. High Court Forgets to Be NICE A court challenge to place limits on treatment for Alzheimer's disease is upheld. Eisai has said it will appeal the High Court's ruling. It's a bit of a high-stakes gamble. The United Kingdom accounts for just a small portion of Eisai's profits from Aricept. |
The Motley Fool
March 31, 2008
Rich Duprey |
Teva's Tough Pill to Swallow Eisai wins a preliminary injunction against Teva's generic Alzheimer's treatment. |
The Motley Fool
June 29, 2007
Rich Duprey |
No More Mr. NICE Guy Pharmaceuticals take British advisory agency to court to approve Alzheimer's treatment. |
Chemistry World
March 27, 2013
Eugene Gerden |
Russian investment vehicle sets sights on innovative drugs Russian state-owned nanotechnology giant Rusnano is hoping to break into the pharmaceutical sector with sizeable investments in firms seeking to produce innovative drugs. |
The Motley Fool
November 1, 2005
Rich Duprey |
Eisai's Good Medicine The Japanese pharmaceutical reports record sales and earnings on the strength of its Alzheimer's treatment. Sales and profit growth have caused Eisai's share price to surge by about 33% since the beginning of the year. |
The Motley Fool
January 18, 2005
Brian Gorman |
Cardinal Doesn't Get Ruffled The drug distributor's potential loss of Japanese pharmaceutical Eisai will hurt in the short term, but fortunately for investors Cardinal Health continues to plan wisely. |
Chemistry World
December 2009 |
Column: In the pipeline Is the pharmaceutical industry churning out copycat versions of existing therapies? The author dispels a few myths about 'me-too' drugs |
The Motley Fool
May 29, 2008
Brian Lawler |
Ligand Loses, for Now The FDA sends Ligand Pharmaceutical this message: approval unlikely, try again later. |
The Motley Fool
November 21, 2008
Brian Orelli |
Ligand and Glaxo Like the FDA's Answer Good news arrives for blood-clot buster Promacta. |
Chemistry World
September 7, 2008
Simon Hadlington |
Coupled proteins to reveal drug hits Researchers in France have successfully attached an 'electrical switch' to a key class of membrane proteins targeted by many drugs. |
Reason
April 2001
Ronald Bailey |
Goddamn the Pusher Man Why does everybody seem to hate the pharmaceutical industry? |
The Motley Fool
April 4, 2007
Brian Lawler |
Companies That Pay Out ... and Drop Here is an explanation of why a stock price falls after a large one-time dividend payout. |
The Motley Fool
March 7, 2007
Rich Duprey |
Eisai Courts Danger The start of a patent-infringement trial sets the stage for the Japanese pharmaceutical's loss of protection on a major drug. |
The Motley Fool
April 17, 2007
Rich Duprey |
Eisai Says Sayonara The Japanese company withdraws its application for approval of its Alzheimer's drug for severe cases of the disease in Europe. What will it mean to investors? |
Chemistry World
November 7, 2014
Katrina Kramer |
Stressed ligands switch catalysis selectivity Researchers have discovered that enantioselectivity in palladium-catalyzed reactions depends on the ligand's intramolecular strain. |
